Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
Abstract
Background. A large proportion of patients with amnestic mild cognitive impairment (MCI) convert to Alzheimer's disease (AD) and hence acetylcholinesterase inhibitors (ACheI) are commonly prescribed in patients with MCI though it is not FDA approved for this condition. Therefore, predicting which MCI patients are likely to improve cognitively with ACheI treatment is important. Hypotheses. 1. The acute decrease in UPSIT (Odor identification test) scores from pre- to post- atropine nasal spray challenge conducted at baseline (0 weeks) will be associated with cognitive improvement (SRT total recall and modified ADAS-cog) from baseline to 26 weeks and 52 weeks of donepezil treatment. 2. Increase in UPSIT scores from baseline to 8 weeks of donepezil treatment will be associated with cognitive improvement from baseline to 26 and 52 weeks. Exploratory Hypothesis. The acute atropine-induced decrease in UPSIT scores, and increase in UPSIT scores from baseline to 8 weeks, will be associated with a decreased likelihood of conversion to dementia at 52 weeks. Study Design. In this proof of concept study, 60 patients with mild cognitive impairment will be treated openly with donepezil 5 to 10 mg per day and followed for 52 weeks (one year), with an atropine challenge test also conducted at baseline.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2016
- Accession Number
- ADA635946
Entities
People
- Davangere Devanand
Organizations
- Columbia University